Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-PD-L1 antibodies, have shown promise in treating some gynecological cancers by blocking the PD-1/PD-L1 interaction and enhancing the immune response [100]. Here, CD274 is linked to female reproductive organ cancer.